OXYBUTYNIN CHLORIDE

Oxybutynin Chloride Adverse Events Reported to the FDA Over Time

How are Oxybutynin Chloride adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Oxybutynin Chloride, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Oxybutynin Chloride is flagged as the suspect drug causing the adverse event.

Most Common Oxybutynin Chloride Adverse Events Reported to the FDA

What are the most common Oxybutynin Chloride adverse events reported to the FDA?

Dry Mouth	86 (2.74%)
Drug Ineffective	81 (2.59%)
Confusional State	47 (1.5%)
Dizziness	44 (1.4%)
Constipation	41 (1.31%)
Fall	35 (1.12%)
Nausea	34 (1.09%)
Somnolence	31 (.99%)
Vomiting	31 (.99%)
Vision Blurred	30 (.96%)
Drug Interaction	29 (.93%)
	Show More
Asthenia	26 (.83%)
Pollakiuria	26 (.83%)
Hypertension	25 (.8%)
Urinary Tract Infection	25 (.8%)
Chest Pain	24 (.77%)
Death	24 (.77%)
Pruritus	24 (.77%)
Dyspnoea	23 (.73%)
Drug Exposure During Pregnancy	22 (.7%)
Fatigue	22 (.7%)
Malaise	22 (.7%)
Pain	22 (.7%)
Completed Suicide	21 (.67%)
Urinary Incontinence	21 (.67%)
Abdominal Pain	20 (.64%)
Talipes	20 (.64%)
Insomnia	19 (.61%)
Hallucination	18 (.57%)
Headache	18 (.57%)
Chest Discomfort	17 (.54%)
Diarrhoea	16 (.51%)
Loss Of Consciousness	16 (.51%)
Anxiety	15 (.48%)
Mental Status Changes	15 (.48%)
Oedema Peripheral	15 (.48%)
Pyrexia	15 (.48%)
Aggression	14 (.45%)
Agitation	14 (.45%)
Amnesia	14 (.45%)
Back Pain	14 (.45%)
Cognitive Disorder	14 (.45%)
Congenital Musculoskeletal Anomaly	14 (.45%)
Dehydration	14 (.45%)
Disorientation	14 (.45%)
Alanine Aminotransferase Increased	13 (.41%)
Aspartate Aminotransferase Increase...	13 (.41%)
Dyspepsia	13 (.41%)
Medication Error	13 (.41%)
Rib Hypoplasia	13 (.41%)
Spine Malformation	13 (.41%)
Blood Alkaline Phosphatase Increase...	12 (.38%)
Cerebrovascular Accident	12 (.38%)
Condition Aggravated	12 (.38%)
Convulsion	12 (.38%)
Delirium	12 (.38%)
Gait Disturbance	12 (.38%)
Hyponatraemia	12 (.38%)
Rash	12 (.38%)
Suicidal Ideation	12 (.38%)
Tremor	12 (.38%)
Abdominal Pain Upper	11 (.35%)
Blood Pressure Increased	11 (.35%)
Dry Eye	11 (.35%)
Dysuria	11 (.35%)
Memory Impairment	11 (.35%)
Pulmonary Hypoplasia	11 (.35%)
Renal Failure	11 (.35%)
Urticaria	11 (.35%)
Weight Decreased	11 (.35%)
Anorexia	10 (.32%)
Dry Throat	10 (.32%)
Dyskinesia	10 (.32%)
Gastrooesophageal Reflux Disease	10 (.32%)
Limb Malformation	10 (.32%)
Lung Disorder	10 (.32%)
Nocturia	10 (.32%)
Overdose	10 (.32%)
Tachycardia	10 (.32%)
Weight Increased	10 (.32%)
Balance Disorder	9 (.29%)
Bradycardia	9 (.29%)
Caesarean Section	9 (.29%)
Congenital Anomaly	9 (.29%)
Decreased Appetite	9 (.29%)
Drug Effect Decreased	9 (.29%)
Intestinal Obstruction	9 (.29%)
Pulmonary Malformation	9 (.29%)
Renal Failure Acute	9 (.29%)
Speech Disorder	9 (.29%)
Unevaluable Event	9 (.29%)
Urinary Retention	9 (.29%)
Cyanosis Neonatal	8 (.26%)
Feeling Abnormal	8 (.26%)
Hallucination, Visual	8 (.26%)
Hypersensitivity	8 (.26%)
Muscle Spasms	8 (.26%)
Muscular Weakness	8 (.26%)
Myalgia	8 (.26%)
Pain In Extremity	8 (.26%)
Product Quality Issue	8 (.26%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Oxybutynin Chloride, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Oxybutynin Chloride is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Oxybutynin Chloride

What are the most common Oxybutynin Chloride adverse events reported to the FDA?

Neurological	176 (5.62%)
Gastrointestinal Signs	143 (4.56%)
Therapeutic And Nontherapeutic Effe...	140 (4.47%)
Urinary Tract Signs	110 (3.51%)
Salivary Gland Conditions	90 (2.87%)
Epidermal And Dermal Conditions	88 (2.81%)
Musculoskeletal And Connective Tiss...	77 (2.46%)
Respiratory	76 (2.43%)
Gastrointestinal Motility And Defec...	74 (2.36%)
Deliria	73 (2.33%)
Injuries	64 (2.04%)
	Show More
Infections - Pathogen Unspecified	58 (1.85%)
Medication Errors	56 (1.79%)
Mental Impairment	49 (1.56%)
Cardiac Arrhythmias	46 (1.47%)
Movement Disorders	46 (1.47%)
Vision	43 (1.37%)
Musculoskeletal And Connective Tiss...	41 (1.31%)
Anxiety Disorders	38 (1.21%)
Suicidal And Self-injurious Behavio...	37 (1.18%)
Disturbances In Thinking	36 (1.15%)
Electrolyte And Fluid Balance Condi...	36 (1.15%)
Hepatobiliary	34 (1.09%)
Cardiac And Vascular Investigations	33 (1.05%)
Chemical Injury And Poisoning	33 (1.05%)
Fatal Outcomes	33 (1.05%)
Psychiatric	32 (1.02%)
Renal Disorders	32 (1.02%)
Muscle	30 (.96%)
Seizures	28 (.89%)
Skin Appendage Conditions	26 (.83%)
Sleep Disorders	26 (.83%)
Physical Examination Topics	25 (.8%)
Vascular Hypertensive	25 (.8%)
Hepatic And Hepatobiliary	24 (.77%)
Eye	23 (.73%)
Appetite And General Nutritional	22 (.7%)
Lower Respiratory Tract Disorders	21 (.67%)
Respiratory Disorders Congenital	21 (.67%)
Body Temperature Conditions	19 (.61%)
Central Nervous System Vascular	19 (.61%)
Headaches	19 (.61%)
Joint	19 (.61%)
Personality Disorders	18 (.57%)
Decreased And Nonspecific Blood Pre...	17 (.54%)
Heart Failures	17 (.54%)
Renal And Urinary Tract Investigati...	17 (.54%)
Lifestyle Issues	15 (.48%)
Angiedema And Urticaria	14 (.45%)
Enzyme	14 (.45%)
Hematology Investigations	14 (.45%)
Congenital And Hereditary	13 (.41%)
Gastrointestinal Stenosis And Obstr...	13 (.41%)
Procedural And Device Related Injur...	13 (.41%)
Upper Respiratory Tract Disorders	13 (.41%)
Administration Site Reactions	12 (.38%)
Allergic Conditions	12 (.38%)
Bacterial Infectious	12 (.38%)
Bladder And Bladder Neck Disorders	12 (.38%)
Bone And Joint Therapeutic Procedur...	12 (.38%)
Dental And Gingival Conditions	12 (.38%)
Metabolic, Nutritional And Blood Ga...	12 (.38%)
Product Quality Issues	12 (.38%)
Encephalopathies	11 (.35%)
Obstetric And Gynecological Therape...	11 (.35%)
Oral Soft Tissue Conditions	11 (.35%)
Therapeutic Procedures And Supporti...	11 (.35%)
Depressed Mood Disorders	10 (.32%)
Mood Disorders	10 (.32%)
Musculoskeletal And Connective Tiss...	10 (.32%)
Bone And Joint Injuries	9 (.29%)
Cardiac Disorder Signs	9 (.29%)
Coronary Artery	9 (.29%)
Lipid Analyses	9 (.29%)
Neuromuscular	9 (.29%)
Ocular Neuromuscular	9 (.29%)
Gastrointestinal Conditions	8 (.26%)
Inner Ear And Viiith Cranial Nerve	8 (.26%)
Neonatal Respiratory	8 (.26%)
Structural Brain	8 (.26%)
Tongue Conditions	8 (.26%)
Arteriosclerosis, Stenosis, Vascula...	7 (.22%)
Bone Disorders	7 (.22%)
Gastrointestinal Neoplasms Malignan...	7 (.22%)
Maternal Complications Of Labour An...	7 (.22%)
Neonatal And Perinatal Conditions	7 (.22%)
Ocular Structural Change, Deposit A...	7 (.22%)
Pulmonary Vascular	7 (.22%)
Water, Electrolyte And Mineral	7 (.22%)
White Blood Cell	7 (.22%)
Abortions And Stillbirth	6 (.19%)
Changes In Physical Activity	6 (.19%)
Gallbladder	6 (.19%)
Gastrointestinal Hemorrhages	6 (.19%)
Glaucoma And Ocular Hypertension	6 (.19%)
Hypothalamus And Pituitary Gland	6 (.19%)
Renal And Urinary Tract Therapeutic...	6 (.19%)
Schizophrenia And Other Psychotic	6 (.19%)
Vascular	6 (.19%)
Vascular Hemorrhagic	6 (.19%)
Viral Infectious	6 (.19%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Oxybutynin Chloride, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Oxybutynin Chloride is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.